Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
3.600
-0.070 (-1.91%)
At close: Feb 27, 2026, 4:00 PM EST
3.630
+0.030 (0.83%)
After-hours: Feb 27, 2026, 4:04 PM EST
Pluri Revenue
Pluri had revenue of $198.00K in the quarter ending December 31, 2025, with 7.03% growth. This brings the company's revenue in the last twelve months to $1.34M, up 97.49% year-over-year. In the fiscal year ending June 30, 2025, Pluri had annual revenue of $1.34M with 309.82% growth.
Revenue (ttm)
$1.34M
Revenue Growth
+97.49%
P/S Ratio
27.02
Revenue / Employee
$9,430
Employees
142
Market Cap
36.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.34M | 1.01M | 309.82% |
| Jun 30, 2024 | 326.00K | 39.00K | 13.59% |
| Jun 30, 2023 | 287.00K | 53.00K | 22.65% |
| Jun 30, 2022 | 234.00K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | 23.00K | -31.00K | -57.41% |
| Jun 30, 2019 | 54.00K | 4.00K | 8.00% |
| Jun 30, 2018 | 50.00K | - | - |
| Jun 30, 2017 | - | - | - |
| Jun 30, 2016 | 2.85M | 2.47M | 651.19% |
| Jun 30, 2015 | 379.00K | - | - |
| Jun 30, 2014 | 379.00K | -300.00K | -44.18% |
| Jun 30, 2013 | 679.00K | -37.00K | -5.17% |
| Jun 30, 2012 | 716.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | - | - | - |
| Jun 30, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 40.58M |
| NovaBay Pharmaceuticals | 10.30M |
| Palatin Technologies | 8.96M |
| CervoMed | 6.16M |
| Lisata Therapeutics | 1.07M |
| Outlook Therapeutics | 205.70K |
| Actinium Pharmaceuticals | 90.00K |
PLUR News
- 2 months ago - Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - GlobeNewsWire
- 9 months ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 10 months ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 1 year ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 1 year ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 1 year ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 1 year ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 1 year ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire